Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Pan-tumor × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1090 Neoplasms 945 Carcinoma, Non-Small-Cell Lung 681 Prostatic Neoplasms 630 Colorectal Neoplasms 510 Lung Neoplasms 505 Pancreatic Neoplasms 356 Leukemia, Myeloid, Acute 349 Neoplasm Metastasis 334 Multiple Myeloma 329 Ovarian Neoplasms 321 Carcinoma, Hepatocellular 284 Stomach Neoplasms 280 Melanoma 259 Recurrence 253 Squamous Cell Carcinoma of Head and Neck 238 Brain Neoplasms 235 Lymphoma 217 Endometrial Neoplasms 215 Precursor Cell Lymphoblastic Leukemia-Lymphoma 213 Uterine Cervical Neoplasms 209 Head and Neck Neoplasms 205 Triple Negative Breast Neoplasms 202 Glioblastoma 199 Urinary Bladder Neoplasms 185 Sarcoma 184 Hematologic Neoplasms 178 Carcinoma, Renal Cell 178 Esophageal Neoplasms 175 Lymphoma, Non-Hodgkin 163

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡